Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SBC vs ACCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

SBC Overall Winner 6-Pillar Tally: SBC 4 – 1 ACCL (1 Tie) Matrix Metrics: SBC 8 – 2 ACCL

As of Nov 16, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over ACCL (ACCL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBC carries a Unified Composite Score of 47.6/100 (HOLD) at $6.42 (13.6x Forward P/E, 37.3% operating margin), whereas ACCL carries 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin).

  • Composite vs. Pillar Nuance: While ACCL currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. SBC 47.6/100 HOLD), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (37.3% vs. 4.5% operating margin) and revenue trajectory (+13.4% vs. +11.3% YoY).
  • Technical & Structure Timing Caution: SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.9); meanwhile ACCL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SBC vs ACCL
SBC NASDAQ Head-to-Head Winner
SBC Medical Group Holdings Incorporated Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$6.42
-12.65% 1D
Market Cap $549.2M
TTM Revenue $175M
Forward P/E 13.6x
Beta / 30D Vol 0.65β · 150% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 15.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.7% over 20 days), RSI 62
RSI-14: 61.9 · SMA20: $5.49 · SMA50: $5.17
ACCL US Equity
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap $33.5M
TTM Revenue $5.2M
Forward P/E N/M
Beta / 30D Vol -0.20β · 60% Vol
Unified Composite Score
63.4 / 100 BUY
Tech 68.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 39
RSI-14: 39.2 · SMA20: $2.54 · SMA50: $2.65

6-Pillar Scorecard Institutional Category Breakdown (SBC 4 – 1 ACCL)

Columns: Metric · SBC · ACCL
1. Valuation Multiples SBC
Forward P/E 13.6x N/M
Trailing P/E 11.4x 120.0x
PEG Ratio 2.02x N/M
EV / Revenue 3.1x 6.5x
2. Growth & Scale SBC
Revenue Growth (YoY) +13.4% +11.3%
Earnings Growth (YoY) +338.9% -62.5%
TTM Revenue (USD) $175M $5.2M
Market Cap $549.2M $33.5M
3. Profitability & Quality SBC
Gross Margin 71.9% 42.4%
Operating Margin 37.3% 4.5%
Net Profit Margin 28.0% 5.5%
Return on Equity (ROE) 18.9% 7.0%
4. Balance Sheet & Cash Flow SBC
Cash Generation (TTM) $69M EBITDA $245,425 EBITDA
Cash Flow Margin 39.2% EBITDA Mgn 4.7% EBITDA Mgn
Net Cash / Leverage $2.57 Book/Sh · 18.9% ROE $0.43 Book/Sh · 7.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ACCL
OpEx & R&D Intensity 34.6% of Rev ($61M) 37.9% of Rev ($2.0M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Consulting Services Operator Consulting Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SBC (8) vs ACCL (2)
Institutional Metric SBC ACCL Criterion Row Edge
Market Capitalization
Scale
$549.2M $33.5M Larger Scale SBC
Trailing P/E Ratio
Valuation
11.4x 120.0x Lower Multiple SBC
Forward P/E Ratio
Valuation
13.6x N/M Lower Multiple SBC
Revenue Growth (YoY)
Growth
+13.4% +11.3% Higher Growth SBC
Operating Margin (TTM)
Profitability
37.3% 4.5% Higher Margin SBC
Net Profit Margin
Profitability
28.0% 5.5% Higher Margin SBC
Return on Equity (ROE)
Capital Efficiency
18.9% 7.0% Higher ROE SBC
52-Week Range Position
Momentum
79% ($3–$7) 30% ($1–$5) Stronger Trend SBC
Beta / 30D Volatility
Risk Regime
0.65β · 150% Vol -0.20β · 60% Vol Lower Realized Risk ACCL
Unified Institutional Score
Composite Signal
47.6 / 100 (HOLD) 63.4 / 100 (BUY) Higher Composite ACCL
Trailing 12M Revenue (USD)
Operating Scale
$175M $5.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.9% 42.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.02x PEG · 3.1x EV/Rev N/M PEG · 6.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$69M EBITDA ($2.57 Book/Sh · 18.9% ROE) $245,425 EBITDA ($0.43 Book/Sh · 7.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBC +35.01 pp
SBC: +22.75% · ACCL: -12.26%
3M Horizon SBC +92.31 pp
SBC: +75.41% · ACCL: -16.9%
6M Horizon SBC +54.89 pp
SBC: +115.44% · ACCL: +60.55%
1Y Horizon SBC +134.74 pp
SBC: +91.07% · ACCL: -43.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SBC vs ACCL. Trailing 12-month operating profitability (SBC 37.3% vs ACCL 4.5%) and valuation multiples (SBC 13.6x vs ACCL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SBC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$175M
Gross Margin71.9%
Op. Margin37.3%
ROE / Fwd P/E18.9% · 13.6x
ACCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.2M
Gross Margin42.4%
Op. Margin4.5%
ROE / Fwd P/E7.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SBC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SBC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SBC Moat Profile High-Margin Pricing Power Moat
Consulting Services Operator
Competes within the Consulting Services value chain with $549.2M market capitalization and 37.3% operating margin.
OpEx & R&D Reinvestment 34.6% of Rev ($61M)
90D Engineering Disclosures 0 Published
ACCL Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $33.5M market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment 37.9% of Rev ($2.0M)
90D Engineering Disclosures 0 Published

Investor FAQ SBC vs ACCL Key Questions & Quantitative Answers

As of Nov 16, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over ACCL (ACCL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBC carries a Unified Composite Score of 47.6/100 (HOLD) at $6.42 (13.6x Forward P/E, 37.3% operating margin), whereas ACCL carries 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin). Composite vs. Pillar Nuance: While ACCL currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. SBC 47.6/100 HOLD), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (37.3% vs. 4.5% operating margin) and revenue trajectory (+13.4% vs. +11.3% YoY). Technical & Structure Timing Caution: SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.9); meanwhile ACCL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SBC leads the Growth & Scale pillar: SBC posts +13.4% YoY revenue growth and +338.9% YoY earnings growth on $175M TTM revenue (71.9% gross margin, 37.3% operating margin), compared with ACCL at +11.3% YoY revenue growth and -62.5% YoY earnings growth on $5.2M TTM revenue (42.4% gross margin, 4.5% operating margin). On trailing 12-month operating scale, SBC generates $175M in USD-normalized revenue versus $5.2M for ACCL. In operating R&D and SG&A reinvestment, SBC deploys 34.6% of Rev ($61M) (0 90-day corporate R&D disclosures) versus 37.9% of Rev ($2.0M) (0 disclosures) for ACCL.

SBC screens cheaper on headline valuation multiples. SBC trades at 13.6x Forward P/E, 11.4x Trailing P/E, 2.02x PEG, and 3.1x EV/Revenue (39.2% EBITDA margin), whereas ACCL trades at N/M Forward P/E, 120.0x Trailing P/E, N/M PEG, and 6.5x EV/Revenue (4.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SBC (18.9% ROE) versus ACCL (7.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SBC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 150% Vol realized risk). By comparison, ACCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.